

Saskatchewan Health Authority - Saskatoon Area Antibioqram 2018

ICU/CCU PATIENTS-All isolates (including Urinary isolates)

January 1, 2018 - December 31, 2018

Inpatients – % Susceptible

	# Isolates tested	Penicillin PO/IV	Penicillin IV - meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalixin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin	
GRAM-NEGATIVE BACTERIA																											
<i>Escherichia coli</i> ¹	145			30		80	92		39	89		48		47	97	97					83		79	93	93		
<i>Enterobacter cloacae</i> ²	38			R		R	R		R	R		R		R	97	66					100		97	100	100		
<i>Haemophilus influenzae</i> ‡	29			79							96	100						100				100	79				
<i>Klebsiella pneumoniae</i> ¹	42			R		100	100		92	97		92		92	100	100					100		100	100	100		
<i>Pseudomonas aeruginosa</i>	86						67							70	62						61			81	94		

	# Isolates tested	Penicillin PO/IV	Penicillin IV - meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalixin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin ³	Tobramycin	Vancomycin
GRAM-POSITIVE BACTERIA																										
<i>Staphylococcus aureus</i> , all																										
- methicillin-susceptible (MSSA)	103				100		100									79		78	95	99	99	97	100			100
- methicillin-resistant (MRSA)	58	R	R	R	R	R	R	R	R	R	R	R	R	R	R	59		47	100	57	57	98	100			100
<i>Streptococcus pneumoniae</i>	33	97	88								94	100	94		100		90		88			100				100
<i>Enterococcus faecalis</i> ‡	25			100				R	R	R	R	R	R						R	30	83			91		100
<i>Enterococcus faecium</i>	35			R				R	R	R	R	R	R						R	68	R			95		41

R - intrinsically resistant

‡ Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

¹ 5.8 % of combined *E.coli*, and *K.pneumoniae* isolates were ESBL (extended spectrum beta-lactamase) positive

² these organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite *in vitro* susceptibility

³ susceptibility to gentamicin in gram positive organisms refers to combination synergy treatment only